Lyle D. Burgoon, PhD
About
Dr. Lyle D. Burgoon is a toxicologist specializing in pharmacology, occupational toxicology, and risk and hazard assessment. He serves as President and CEO of Raptor Pharm & Tox, Ltd., where his work centers on evaluating chemical safety and human health risk.
With 93 peer-reviewed publications, Dr. Burgoon has contributed to research across a broad range of toxicological topics. His work has appeared in journals including Environmental Health Perspectives, Archives of Toxicology, Regulatory Toxicology and Pharmacology, the Journal of Agricultural and Food Chemistry, and Pediatrics. Recent publications address the endocrine disruptive potential of siloxane compounds, dose-response modeling for human carcinogenicity assessments, PFOA safe dose estimation through international collaboration, and the influence of dataset selection on quantitative structure-activity relationship models used to predict toxicant behavior. He has also submitted expert commentary to the U.S. Environmental Protection Agency in regulatory proceedings.
Dr. Burgoon's professional focus encompasses chemical risk assessment, toxicant prediction methodology, and the evaluation of environmental and occupational exposures, areas directly relevant to litigation involving toxic tort claims, regulatory compliance disputes, and exposure-related health questions.
Credentials
Publications
- Challenges and Opportunities in the Development and Adoption of New Approach Methods (NAMs).
- Octamethylcyclotetrasiloxane (D4) lacks endocrine disruptive potential via estrogen pathways.
- Kinetically-derived maximal dose (KMD) confirms lack of human relevance for high-dose effects of octamethylcyclotetrasiloxane (D4).
- A Late Night Page and a Lesson on Health Literacy.
- The database makes the poison: How the selection of datasets in QSAR models impacts toxicant prediction of higher tier endpoints.
- Range of the perfluorooctanoate (PFOA) safe dose for human health: An international collaboration.
- The physiological and biochemical basis of potency thresholds modeled using human estrogen receptor alpha: implications for identifying endocrine disruptors.
- Kinetically-derived maximal dose (KMD) indicates lack of human carcinogenicity of ethylbenzene.
- Understanding and overcoming the technical challenges in using in silico predictions in regulatory decisions of complex toxicological endpoints - A pesticide perspective for regulatory toxicologists with a focus on machine learning models.
- Comment on "Application of an in Vitro Assay to Identify Chemicals That Increase Estradiol and Progesterone Synthesis and Are Potential Breast Cancer Risk Factors".
Request CV and rates
Tell us about your case and we'll connect you with Lyle D. Burgoon, PhD within two business days.
Other Toxicology experts
Verified specialists available for your case.